Evidence map›Paper›PMID 25831499›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Phosphorylation of ORF1p is required for L1 retrotransposition.

Pamela R Cook, Charles E Jones, Anthony V Furano

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Retrotransposon Protein L1 ORF1p Expression in Aging Central Nervous System.International journal of molecular sciences · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. LINE-1 expression in cancer correlates with p53 mutation, copy number alteration, and S phase checkpoint.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  16. Review
  17. Article
  18. Article
  19. Human TRIM5α senses and restricts LINE-1 elements.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pamela R CookLaboratory of Cell and Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0850.
Charles E JonesLaboratory of Cell and Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0850.
Anthony V FuranoLaboratory of Cell and Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0850 avf@helix.nih.gov.

Funding

Mammalian L1 retrotransposon replicationZIADK057601 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI FURANO, ANTHONY V. · 2009 to 2022
$7.2M
Intramural NIH HHS
6 · The paper itself

Abstract

Although members of the L1 (LINE-1) clade of non-LTR retrotransposons can be deleterious, the L1 clade has remained active in most mammals for ∼100 million years and generated almost 40% of the human genome. The details of L1-host interaction are largely unknown, however. Here we report that L1 activity requires phosphorylation of the protein encoded by the L1 ORF1 (ORF1p). Critical phospho-acceptor residues (two serines and two threonines) reside in four conserved proline-directed protein kinase (PDPK) target sites. The PDPK family includes mitogen-activated protein kinases and cyclin-dependent kinases. Mutation of any PDPK phospho-acceptor inhibits L1 retrotransposition. The phosphomimetic aspartic acid can restore activity at the two serine sites, but not at either threonine site, where it is strongly inhibitory. ORF1p also contains conserved PDPK docking sites, which promote specific interaction of PDPKs with their targets. As expected, mutations in these sites also inhibit L1 activity. PDPK mutations in ORF1p that inactivate L1 have no significant effect on the ability of ORF1p to anneal RNA in vitro, an important biochemical property of the protein. We show that phosphorylated PDPK sites in ORF1p are required for an interaction with the peptidyl prolyl isomerase 1 (Pin1), a critical component of PDPK-mediated regulation. Pin1 acts via isomerization of proline side chains at phosphorylated PDPK motifs, thereby affecting substrate conformation and activity. Our demonstration that L1 activity is dependent on and integrated with cellular phosphorylation regulatory cascades significantly increases our understanding of interactions between L1 and its host.

Indexed as

Long Interspersed Nucleotide ElementsOpen Reading Frames3-Phosphoinositide-Dependent Protein KinasesAmino Acid MotifsAmino Acid SequenceAnimalsBinding SitesChromatography, LiquidGlutathione TransferaseHeLa CellsHumansInsectaMolecular Sequence DataMutationNIMA-Interacting Peptidylprolyl IsomerasePeptidylprolyl Isomerase3-Phosphoinositide-Dependent Protein KinasesGlutathione TransferaseNIMA-Interacting Peptidylprolyl IsomerasePDPK1 protein, humanPeptidylprolyl IsomerasePIN1 protein, humanProlineRetroelementsRNAViral ProteinsLINE-1peptidyl prolyl isomerase 1Pin1proline-directed protein kinaseretrotransposon

Identifiers

PMID25831499
PMCPMC4394301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.